Markham, Ontario — Exact Imaging has expanded its U.S. commercial team as demand grows for its high-resolution micro-ultrasound system used in targeted prostate cancer biopsies.
The company promoted Tim Heyer to vice president of North American sales and appointed Drew Moore as sales executive for the Northeast region. Exact Imaging also plans to hire representatives for the Midwest and West Coast and expects to have four to five regional sales professionals by the end of the year.
Heyer, a U.S. Marine Corps veteran, has 35 years of experience in medical device sales and service and has helped launch three devices cleared by the U.S. Food and Drug Administration.
He previously served as vice president of sales and service at EDAP Technomed, where he built the organization supporting the Prostatron urology system before its FDA approval in 1996. He later led a mobile urology services business that expanded from eight states to 42 states before its acquisition by Boston Scientific in 2007.
Moore has more than 20 years of medical sales experience and established relationships in the U.S. urology market, the company said.
“My focus has always been on building strong relationships with physicians and understanding their needs for providing the best care for their patients,” said Mr. Heyer. “As we grow our presence in the U.S., Exact Imaging is committed to making sure more urologists have access to our proven micro-ultrasound technology.”
Exact Imaging said several academic and community health centers in the United States have recently installed additional systems, reflecting increased adoption of micro-ultrasound as an alternative or complement to MRI for detecting prostate cancer.
“We are seeing accelerated demand for our technology in North America and throughout the rest of the world,” said Randy AuCoin, chief executive officer of Exact Imaging. “Investing in our sales team is our top priority as it ensures we have the resources and momentum to support the growing number of physicians and health systems adopting our micro-ultrasound platform.”
The company is also conducting research involving image-guided biopsies, focal therapy and active surveillance.
